Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.38Same Quarter Last Year
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -18.02%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, increased collaboration revenue for the quarter, and a strong cash position. However, minimal year-over-year revenue growth and sustained high R&D expenses present challenges.Company Guidance
During Alector's earnings call, the company provided guidance on several key metrics and upcoming milestones. They anticipate a significant portion of the company's potential to be realized in 2025, with expectations to complete patient recruitment for the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease by mid-2025. Additionally, they plan to read out the pivotal Phase 3 trial in frontotemporal dementia with progranulin gene mutation by the fourth quarter of this year. Financially, Alector expects collaboration revenue for 2025 to range between $5 million and $15 million, with research and development expenses projected to be between $175 million and $185 million, and general and administrative expenses estimated to be between $55 million and $65 million. The company is optimistic about advancing its wholly-owned programs using the Alector Brain Carrier technology, with clinical trials expected in 2026, and they remain committed to creating sustainable value through data-driven decisions.Increase in Collaboration Revenue
Collaboration revenue for the fourth quarter was $54.2 million compared to $15.2 million for the same period in 2023, indicating a significant increase.
Breakthrough Therapy Designation for Latozinemab
The FDA granted Latozinemab breakthrough therapy designation for FTD granulin based on INFRONT-2 Phase 2 clinical trial data.
Strong Cash Position
As of December 31st, 2024, cash, cash equivalents, and short-term investments totaled $413.4 million, indicating financial robustness to support strategic objectives.
Advanced Clinical Programs
Progress in late-stage clinical programs such as INFRONT-3 Phase 3 trial for frontotemporal dementia and PROGRESS-AD Phase 2 trial for Alzheimer's disease.
---
ALEC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALEC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $1.72 | $1.66 | -3.49% |
| Nov 06, 2024 | $5.24 | $5.64 | +7.63% |
| Aug 07, 2024 | $4.91 | $5.10 | +3.87% |
| May 08, 2024 | $5.19 | $5.20 | +0.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Alector Inc (ALEC) report earnings?
Alector Inc (ALEC) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Alector Inc (ALEC) earnings time?
Alector Inc (ALEC) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALEC EPS forecast?
ALEC EPS forecast for the fiscal quarter 2025 (Q1) is -0.48.
---